Valuation : EyePoint, Inc.

Market Cap 399M 343M 321M 294M 553M 38.12B 555M 3.8B 1.48B 19.21B 1.5B 1.47B 63.59B P/E 2026 *
-1.26x
P/E 2027 * -1.74x
Enterprise Value 76.37M 65.56M 61.37M 56.2M 106M 7.29B 106M 727M 284M 3.68B 287M 281M 12.17B EV / Sales 2026 *
44.4x
EV / Sales 2027 * 4.73x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : EyePoint, Inc.

1 day-7.21%
1 week-14.26%
Current month-62.20%
1 month-62.69%
3 months-64.82%
6 months-73.63%
Current year-74.66%
1 week 4.5
Extreme 4.5
5.35
1 month 3.95
Extreme 3.95
14.76
Current year 3.95
Extreme 3.95
18.87
1 year 3.95
Extreme 3.95
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
40.2
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-7.21%-14.26%-60.90%-59.06% 399M
-1.12%-5.49%+60.19%+112.43% 1,048B
-1.57%-0.60%+50.33%+59.86% 640B
-1.81%-1.41%+24.07%+75.98% 456B
-0.44%-3.49%+38.89%+39.88% 362B
+0.05%-2.15%+22.79%+37.83% 295B
+0.07%+0.56%+2.07%+12.16% 255B
-0.76%+0.75%+51.75%+70.45% 236B
+0.91%-1.45%-17.36%-54.14% 204B
+0.52%+3.78%+30.67%+93.68% 185B
Average -0.89%-2.73%+20.25%+38.91% 368.2B
Weighted average by Cap. -0.26%-1.92%+38.56%+65.85%

Financials

2026 *2027 *
Net sales 1.72M 1.48M 1.38M 1.27M 2.38M 164M 2.39M 16.37M 6.4M 82.81M 6.46M 6.32M 274M 17.92M 15.38M 14.4M 13.19M 24.84M 1.71B 24.92M 171M 66.67M 863M 67.29M 65.83M 2.86B
Net income -345M -296M -277M -254M -478M -32.91B -479M -3.28B -1.28B -16.59B -1.29B -1.27B -54.9B -292M -251M -235M -215M -405M -27.89B -406M -2.78B -1.09B -14.06B -1.1B -1.07B -46.53B
Net Debt -323M -277M -259M -238M -447M -30.83B -449M -3.07B -1.2B -15.54B -1.21B -1.19B -51.42B -314M -270M -253M -231M -436M -30.03B -437M -2.99B -1.17B -15.14B -1.18B -1.16B -50.09B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
27/08/26 US$4.630 -7.21% 5,999,646
26/08/26 US$4.990 -0.30% 3,261,916
25/08/26 US$5.005 +2.77% 4,133,632
24/08/26 US$4.870 -8.46% 4,155,639
21/08/26 US$5.320 -1.48% 8,186,380
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
4.630USD
Average target price
27.36USD
Spread / Average Target
+491.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock